BioMed Research International

BioMed Research International / 2015 / Article
Special Issue

Animal Models of Human Pathology 2014

View this Special Issue

Research Article | Open Access

Volume 2015 |Article ID 251598 | 21 pages | https://doi.org/10.1155/2015/251598

SERCA2 Haploinsufficiency in a Mouse Model of Darier Disease Causes a Selective Predisposition to Heart Failure

Academic Editor: Monica Fedele
Received26 Sep 2014
Revised18 Dec 2014
Accepted23 Dec 2014
Published03 May 2015

Abstract

Null mutations in one copy of ATP2A2, the gene encoding sarco/endoplasmic reticulum Ca2+-ATPase isoform 2 (SERCA2), cause Darier disease in humans, a skin condition involving keratinocytes. Cardiac function appears to be unimpaired in Darier disease patients, with no evidence that SERCA2 haploinsufficiency itself causes heart disease. However, SERCA2 deficiency is widely considered a contributing factor in heart failure. We therefore analyzed Atp2a2 heterozygous mice to determine whether SERCA2 haploinsufficiency can exacerbate specific heart disease conditions. Despite reduced SERCA2a levels in heart, Atp2a2 heterozygous mice resembled humans in exhibiting normal cardiac physiology. When subjected to hypothyroidism or crossed with a transgenic model of reduced myofibrillar Ca2+-sensitivity, SERCA2 deficiency caused no enhancement of the disease state. However, when combined with a transgenic model of increased myofibrillar Ca2+-sensitivity, SERCA2 haploinsufficiency caused rapid onset of hypertrophy, decompensation, and death. These effects were associated with reduced expression of the antiapoptotic Hax1, increased levels of the proapoptotic genes Chop and Casp12, and evidence of perturbations in energy metabolism. These data reveal myofibrillar Ca2+-sensitivity to be an important determinant of the cardiac effects of SERCA2 haploinsufficiency and raise the possibility that Darier disease patients are more susceptible to heart failure under certain conditions.

1. Introduction

In humans, loss of one copy of the ATP2A2 gene causes Darier disease (DD), an acantholytic skin disease [1, 2]. ATP2A2 encodes two alternatively spliced variants of sarco/endoplasmic reticulum Ca2+-ATPase isoform 2 (SERCA2). These are SERCA2b, the ubiquitous endoplasmic reticulum (ER) Ca2+ pump, and SERCA2a, the cardiac and slow-twitch skeletal muscle sarcoplasmic reticulum (SR) Ca2+ pump [3]. In its capacity as the primary cardiac SR Ca2+ pump, SERCA2a facilitates muscle relaxation and replenishes SR Ca2+ stores needed for contraction [3]. Because reduced SERCA2 activity is often observed in heart disease [4] and DD mutations cause reductions in SERCA2 expression and activity [5], one might expect these mutations to lead to heart disease in humans. However, two studies of DD patients with a mean age of ~47 years indicated that cardiac performance is normal and yielded no evidence of heart disease [6, 7]; these findings have been interpreted to suggest that a role for SERCA2 deficiency in heart disease, while relevant in rodent models, may be less important in humans [7]. However, while these results provide compelling evidence that Atp2a2 heterozygosity does not impair cardiac function in middle-aged humans, they do not rule out the possibility that SERCA2 haploinsufficiency can increase susceptibility to disease progression and heart failure.

In earlier studies, ablation of one copy of the Atp2a2 gene in mice of a mixed 129Svj and Black Swiss background caused a reduction in cardiac SERCA2a protein expression to 65% of wild-type (WT) levels, with impaired contractility and relaxation [8]. However, true heart disease was not observed; in fact, the major phenotype of the Atp2a2+/− mice was the development of squamous cell tumors in keratinized epithelial tissues [9, 10]. Later studies on these mice revealed an increased susceptibility to pressure-overload cardiac hypertrophy [11] and a reduction of rate-dependent inotropy in isolated mutant hearts, relative to WT controls [12]. In the current study, we used Atp2a2+/− mice on an inbred FVB/N background; while these heterozygous (HET) mice continued to display effects of SERCA2 haploinsufficiency in keratinized epithelia, cardiac performance was apparently normal, more closely reflecting findings in DD patients [6, 7]. The HET model was well suited to determine if SERCA2 deficiency, while apparently benign under normal conditions, could exacerbate cardiac disease progression. Specifically, we investigated the interaction of SERCA2 haploinsufficiency with hypothyroidism, which is known to impair cardiac performance [13], and alterations in myofibrillar Ca2+-sensitivity, which causes pathological hypertrophy and heart failure [14, 15]. For the latter, double mutant mice were generated by crossing HET mice with transgenic lines expressing the Glu54Lys mutant -tropomyosin, which reduces myofibrillar Ca2+-sensitivity and leads to dilated cardiomyopathy [16, 17], and the Glu180Gly mutant -tropomyosin, which increases myofibrillar Ca2+ sensitivity and causes hypertrophic cardiomyopathy [18, 19]. Our results reveal an unexpected selectivity in the effects of SERCA2 haploinsufficiency in heart, which should be taken into consideration in the management of Darier disease patients.

2. Materials and Methods

2.1. Animal Models

The original Atp2a2+/− line was backcrossed onto the inbred FVB/N background in excess of 15 generations to generate the HET mutant line utilized in this study. This Atp2a2+/− mouse line has been made available to researchers through the Jackson Labs repository. All other mice used in this study, including the WT, the transgenic mouse models carrying the Glu154Lys mutant α-tropomyosin, which has dilated cardiomyopathy (DCM) [16], and the Glu180Gly mutant α-tropomyosin, which has hypertrophic cardiomyopathy (HCM) [18], were also on the inbred FVB/N background. HET mice were bred with the DCM and HCM lines to generate double (DCM/HET and HCM/HET) and single mutant offspring. The hypothyroid model was prepared by treating WT and HET mice with 6-n-propyl thiouracil (PTU) exactly as previously described [20]. All procedures conformed to guidelines published by the NIH (Guide for the Care and Use of Laboratory Animals; publication number 86-23, revised 1996) and were approved by the Institutional Animal Care and Use Committee at the University of Cincinnati.

2.2. Evaluation of Cardiac Function

Anesthesia of mice with ketamine and inactin, analysis of cardiovascular function using pressure transducers inserted into the left ventricle and right femoral vein, delivery of drugs via a cannula in the right femoral vein, and recording and analysis of data were performed exactly as described previously [13]. Analysis of cardiac function by M-mode echocardiography of mice, anesthetized using isoflurane inhalation, and analysis of data were performed exactly as described previously [21].

2.3. Immunoblot Analyses

Hearts were harvested from anesthetized mice and processed for immunoblot analysis as previously described [22]. Phosphorylation of phospholamban (PLN) in response to -adrenergic stimulation was assessed in ventricles from mice that were anesthetized and surgically instrumented as described above and treated with dobutamine (16 ng/g body weight/min). Estimation of protein concentration in total homogenates, resolution of proteins by discontinuous, reducing SDS-PAGE, and immunoblot analyses were carried out as described [22]. All primary and secondary antibodies used have been previously described [22].

2.4. Real-Time Polymerase Chain Reaction

Hearts/ventricles were harvested from anesthetized mice and processed for real-time PCR (RT-PCR) analysis as previously described [22]. In addition to the primer pairs that have been previously described [22, 23], the following were used: Hspa5 (GRP78/BiP), PrimerBank ID number 31981722a1; Hsp90b1 (GRP94), PrimerBank ID number 6755863a1; Casp12 (Caspase 12), PrimerBank ID number 31981868a1; Ddit3 (CHOP), PrimerBank ID number 31982415a1; Eif2ak3 (PERK), PrimerBank ID number 6857781a1; Acox1, PrimerBank ID number 26333821a1; Fabp3, PrimerBank ID number 6753810a1; Orai1, PrimerBank ID number 93277106b1; Stim1, PrimerBank ID number 31981983a2; Hax1, PrimerBank ID number 6754160a1; Rcan2, PrimerBank ID number 46560586c1; and Pparγ, PrimerBank ID number 187960104c1; primers for Pln (phospholamban) were adapted from PrimerBank ID number 213512815c1 (forward primer: 5′ AAGTGCAATACCTCACTCG 3′, reverse primer: 5′ GATCAGCAGCAGACATATC 3′). mRNA levels for Atp2b1 (QT01072106) and Atp2b4 (QT01076271) were determined using QuantiTect Primer Assay Kits (Qiagen).

2.5. Statistics

Results are presented as means ± standard error (SE). Individual comparisons were performed using a two-sided Student’s -test, and a value of <0.05 was considered significant.

3. Results

3.1. Cardiovascular Performance in WT and HET Mice

Cardiovascular performance of adult FVB/N WT and HET mice was analyzed using a pressure transducer in the left ventricle under both basal conditions and upon -adrenergic stimulation with dobutamine. No significant differences were observed in basal heart rate, mean arterial pressure, left ventricular end-diastolic pressure, or maximum rates of left ventricular pressure development or decay (Figure 1). Treatment with dobutamine led to similar changes in both genotypes, with no impairment of chronotropic, inotropic, or lusitropic responses. Rate of left ventricular pressure development was also calculated at 40 mm Hg, to assess possible effects of the small but nonsignificant difference in mean arterial pressure (Figure 1(b)); however the two genotypes had virtually identical responses.

3.2. Effects of Atp2a2 Heterozygosity on Proteins Implicated in Ca2+-Handling

RT-PCR analysis of total RNA from WT and HET hearts revealed that mRNA levels of the Atp2a2 gene, which codes for SERCA2, were reduced to % of WT levels (Figure 2(a)). However, immunoblot analysis of total protein homogenates revealed a much smaller reduction in SERCA2a protein levels (to % of WT levels, Figures 2(b) and 2(c)) in HET hearts. This reduction was associated with an increase (to % of WT levels, Figures 2(b) and 2(d)) in expression of the α2 subunit of the L-type Ca2+-channel, which is the principal Ca2+-uptake mechanism on a beat-to-beat basis. There were no changes in expression of either the ryanodine receptor isoform 2, which mediates Ca2+-release from the SR, or the Na+/Ca2+ exchanger isoform 1 (NCX1, Slc8a1), which is the predominant Ca2+-efflux mechanism in cardiac myocytes, in HET hearts (Figure 2(b)).

SERCA2 activity is negatively regulated by phospholamban (PLN), which binds to the Ca2+-pump in a phosphorylation-dependent manner [24]. Reduced PLN expression and increased PLN phosphorylation on residues Ser16 (PS16) and Thr17 (PT17) can both enhance SERCA2a-mediated SR Ca2+-sequestration [24]. However, immunoblot analysis revealed that PLN expression and baseline phosphorylation (Figure 2(e)) were unaltered in HET hearts. The inotropic and lusitropic effects of -adrenergic stimulation are mediated, at least in part, via increased PLN phosphorylation, which facilitates more robust Ca2+-cycling [24]. The normal increase in the cardiovascular performance of stimulated HET mice raised the possibility that -adrenergic stimulated PLN phosphorylation was augmented to compensate for the reduction in SERCA2a levels. To test this hypothesis, PS16 and PT17 levels were determined in hearts from WT and HET mice stimulated with dobutamine. While PS16 levels were comparable between stimulated WT and HET hearts (Figures 2(f) and 2(g)), PT17 levels were elevated in stimulated HET hearts (by %), when compared to similarly treated WT hearts (Figures 2(f) and 2(h)).

3.3. Atp2a2 Heterozygosity Does Not Exacerbate Cardiac Dysfunction Caused by Hypothyroidism

Hypothyroidism is a well-recognized cardiovascular disease risk factor [25]. Studies in rabbits and mice have shown that it is associated with a reduction in cardiac SERCA2 expression [20, 26], raising the possibility that the impairment of cardiac function caused by hypothyroidism would be greater in Atp2a2 heterozygous individuals. To test this hypothesis, hypothyroidism was induced in WT and HET mice and cardiac performance was assessed by in vivo catheterization. Cardiovascular function was similarly diminished in both WT and HET mice (Figures 3(a)3(f)) under both baseline conditions and upon -adrenergic stimulation.

3.4. Atp2a2 Heterozygosity Has No Appreciable Effect on the Cardiac Phenotype of Transgenic Mice with Dilated Cardiomyopathy

Myofibrillar Ca2+-sensitivity is a major determinant of cardiac function; in addition to altering force development, changes in Ca2+-sensitivity can impact myofibrillar Ca2+-buffering, diastolic Ca2+-levels, and SERCA2-mediated cytosolic Ca2+-clearance [14, 15, 2729]. Transgenic expression of Glu154Lys mutant -tropomyosin in the DCM mouse heart lowers myofibrillar Ca2+ sensitivity, impairs contractility, and leads to dilated cardiomyopathy [16]. In order to determine the effects of SERCA2 haploinsufficiency, double mutant DCM/HET mice were analyzed. DCM/HET mice were viable and appeared normal. The increase in heart weight : body weight (HW : BW) and heart weight : tibial length ratios, determined in 8–10-week-old mice, was similar in both single mutant DCM and double mutant DCM/HET mice (Figure 4(a)). Echocardiographic analyses revealed that cardiac function was not compromised in DCM/HET mice when compared to DCM controls; in fact, fractional shortening and ejection fraction trended slightly higher in DCM/HET hearts (Figure 4(b)). RT-PCR analysis showed that the increases in mRNA levels for Nppa (atrial natriuretic peptide), Myh7 (-myosin heavy chain), and Acta1 (skeletal -actin), as markers of pathological hypertrophy, were not significantly different between DCM and DCM/HET hearts (Figure 4(c)). Atp2a2 mRNA levels, which were reduced to % of WT levels in DCM hearts, were lower in DCM/HET hearts (% of WT levels; Figure 4(d)). However, the reduction in SERCA2a protein was more modest, with expression at % of DCM levels in DCM/HET hearts (Figure 4(e)).

3.5. Atp2a2 Heterozygosity Causes Rapid Progression of Hypertrophy and Decompensation in Transgenic HCM Mice

Increased myofibrillar Ca2+-sensitivity, which impairs relaxation, is associated with hypertrophic cardiomyopathy and has also been reported in end-stage heart failure [14, 15]. Cardiac expression of Glu180Gly mutant -tropomyosin in the HCM transgenic model increases myofibrillar Ca2+-sensitivity, impairs relaxation, leads to development of fibrosis and hypertrophy, and causes death at 5-6 months of age [18]. To determine the effects of SERCA2 haploinsufficiency on the HCM phenotype, double mutant HCM/HET mice were generated as described above. SERCA2 haploinsufficiency caused a rapid onset of heart failure and death; 80% of HCM/HET mice were dead by 5 weeks of age and none survived beyond 6-7 weeks (Figure 5(a)). When compared to age-matched HCM controls, HCM/HET hearts displayed overt hypertrophy with pronounced left atrial remodeling as early as 4 weeks of age (Figure 5(b)). HW : BW ratios were higher in HCM/HET mice (Figure 5(c)), as were ratios of ventricular weight : body weight (Figure 5(d)), indicating that the increase in HW : BW was not simply a consequence of atrial remodeling. Consistent with these changes, mRNA levels for several markers of cardiac remodeling, which have been shown to be elevated in 4-week-old HCM hearts [23], were further increased in HCM/HET hearts; these included Nppa (Figure 5(e)), Myh7 (Figure 5(f)), Acta1 (Figure 5(g)), and Ctgf, encoding connective tissue growth factor (Figure 5(h)).

3.6. Effect of Atp2a2 Heterozygosity on Regulators of Ca2+-Handling and Protein Phosphatases in HCM/HET Hearts

RT-PCR analysis of 4-week-old WT, HCM, and HCM/HET hearts revealed that Atp2a2 mRNA levels, which were reduced to % of WT levels in HCM hearts, were sharply reduced in HCM/HET hearts (to % of WT levels; Figure 6(a)). mRNA levels for PLN, which were maintained at WT levels in HCM hearts, were also reduced in HCM/HET hearts (% of WT levels; Figure 6(b)). However, expression of SERCA2a protein showed a smaller reduction of just % from HCM levels in HCM/HET hearts (Figures 6(c) and 6(d)), with no change seen in PLN protein levels (Figure 6(c)).

In addition to its role in contractility, Ca2+ is a regulator of key signaling cascades in heart; the Ca2+-pools implicated in such regulatory functions are thought to exist in microdomains spatially distinct from bulk SR Ca2+-stores [30], which are probably regulated by sarcolemmal Ca2+ pumps such as the plasma membrane Ca2+-ATPases (PMCA). Impairments in cytosolic bulk Ca2+-handling have the potential to perturb the spatial isolation of these Ca2+-microdomains and can lead to a greater reliance on sarcolemmal Ca2+ pumps for Ca2+-clearance. RT-PCR analysis revealed that mRNA levels for PMCA4 were increased in HCM hearts (% of WT levels) and remained similarly elevated in HCM/HET hearts (Figure 6(e)). In contrast, mRNA levels for PMCA1, which were not significantly altered in HCM hearts, were reduced in HCM/HET hearts (to % of WT levels, Figure 6(f)).

As described above, increased myofibrillar Ca2+-buffering in HCM hearts has the potential to antagonize SR Ca2+-sequestration, with effects on SR/ER Ca2+-store levels. However, as we have previously demonstrated [22], the amplitude of stimulated Ca2+-transients is only modestly reduced in HCM myocytes, which raises the possibility that SR/ER Ca2+-stores may be replenished by alternative mechanisms in these hearts. These can include mediators of store-operated Ca2+-entry (SOCE); indeed, expression of mRNAs for both Orai1 (to % of WT levels) and Stim1 (to % of WT levels), which encode proteins with well-characterized roles in stress-induced SOCE activity [31, 32], was increased in HCM hearts. Unexpectedly, this increase was reversed to WT levels in HCM/HET hearts (Figures 6(g) and 6(h)).

Increased expression or activity of the protein phosphatases calcineurin, protein phosphatase 1 (PP1), and protein phosphatase 2A (PP2A) is strongly associated with pathological hypertrophy and heart failure [3336]. Protein levels of the catalytic subunits of calcineurin (CnA), PP1 (PP1-C), and PP2A (PP2A-C), which reflect expression of the respective holoenzymes, were assessed. While CnA and PP2A-C expression were comparable between HCM and HCM/HET hearts (Figure 6(i)), PP1-C levels were reduced in HCM/HET hearts (Figures 6(i) and 6(j)). To address the possibility that calcineurin activity was augmented in HCM/HET hearts, mRNA levels for regulator of calcineurin 1 (calcipressin-1, Rcan1), a marker of calcineurin activity, were determined by RT-PCR analysis. While there was no difference in Rcan1 levels between HCM and HCM/HET hearts (Figure 6(k)), mRNA levels of Rcan2, which codes for calcipressin-2, were significantly reduced in HCM/HET hearts (% of WT levels; Figure 6(l)).

3.7. Expression of ER Stress Markers and Regulators of Apoptosis in HCM/HET Hearts

The reduction in SERCA2a protein levels, coupled with the downregulation of SOCE-related genes, raised the possibility that ER stress was elevated in HCM/HET hearts. We initially assessed expression of key ER stress markers in HCM hearts. RT-PCR analysis revealed no increase in mRNA for the ER chaperones BiP/GRP78 or GRP94 (Figure 7(a)). However, mRNA for PERK, a major kinase involved in ER stress responses, was increased in HCM hearts (to % of WT levels; Figure 7(b)). Furthermore, mRNAs for the ER stress related proapoptotic proteins CHOP (% of WT levels; Figure 7(c)) and CASP12 (% of WT levels; Figure 7(d)) were also increased in HCM hearts. These changes were associated with an increase (to % of WT levels; Figure 7(e)) in mRNA for the antiapoptotic protein HCLS1 associated protein X-1 (HAX1), which is localized to mitochondria and the SR [37].

There was no increase in mRNA levels for GRP78, GRP94, or PERK in HCM/HET hearts when compared to HCM controls (Figures 7(f) and 7(g)). However, mRNA levels for CHOP (% of HCM levels; Figure 7(h)) and CASP12 (% of HCM levels; Figure 7(i)) were further elevated in HCM/HET hearts. The increase seen in HAX1 mRNA in HCM hearts was reversed in HCM/HET hearts (to % of HCM levels; Figure 7(j)).

3.8. Effect of Atp2a2 Heterozygosity on Regulators of Energy Metabolism in HCM Hearts

Impaired relaxation resulting from an increase in myofibrillar Ca2+-sensitivity can energetically stress the heart [38]. The resultant dysregulation of energy metabolism has been suggested to contribute to the hypertrophic phenotype associated with sarcomeric mutations that increase myofibrillar Ca2+-sensitivity [39, 40]. mRNA levels of Pparγ, encoding peroxisome proliferator-activated receptor gamma, a regulator of lipid metabolism that is implicated in the development of pathological hypertrophy [41], were normal in HCM hearts but reduced in HCM/HET hearts (to % of WT levels; Figure 8(a)). Hearts rely predominantly on lipids for their energy supply [42] and FABP3 is the cardiac/muscle-isoform of fatty acid binding proteins, which mediate the intracellular transport of long-chain fatty acids. Expression of the Fabp3 gene was downregulated (to % of WT levels) in HCM hearts and further reduced in HCM/HET hearts (to % of WT levels; Figure 8(b)). Mitochondrial uptake of long-chain fatty acids is mediated by carnitine palmitoyltransferase 1b (CPT1b), the mRNA levels for which were reduced in HCM (to % of WT levels) and further reduced in HCM/HET (to % of WT levels) hearts (Figure 8(c)). CPT1b-mediated transfer of long-chain fatty acids can be inhibited by malonyl CoA, which is generated from acetyl-CoA by acetyl-CoA carboxylase beta (encoded by Acacb). While Acacb mRNA levels trended lower in HCM hearts, they were downregulated in HCM/HET hearts (to % of WT levels; Figure 8(d)). In addition, mRNA levels for acyl-CoA oxidase 1 (Acox1), which is the first enzyme of the β-oxidation pathway, were also reduced (to % of WT levels) in HCM/HET hearts (Figure 8(e)). Besides lipids, hearts also utilize glucose as an energy source [42]. Glucose uptake in heart is mediated by members of Slc2a glucose transporter family, of which GLUT4 (Slc2a4) is the predominant isoform in cardiac myocytes. mRNA levels for GLUT4 were reduced (to % of WT levels) in HCM hearts, with a more pronounced reduction (to % of WT levels) in HCM/HET hearts (Figure 8(f)).

3.9. Biochemical Effects of Atp2a2 Heterozygosity Seen in HCM/HET Hearts Are Lacking in DCM/HET Hearts

As described above, Atp2a2 heterozygosity did not exacerbate the cardiac disease phenotype of DCM mice. Given the dramatic effects of SERCA2 haploinsufficiency in HCM/HET hearts at the RNA/protein levels, we analyzed DCM/HET hearts to identify possible underlying similarities. Several mRNAs analyzed (Casp12, Fabp3, and Cpt1b) were altered in DCM hearts relative to WT hearts. However, RT-PCR analysis revealed that Atp2a2 heterozygosity did not impact mRNA levels for Ddit3 (CHOP), Casp12, Hax1, Fabp3, Cpt1b, or Slc2a4 (GLUT4) in DCM/HET hearts when compared with DCM hearts (Table 1). Immunoblot analyses of total ventricular homogenates of DCM and DCM/HET mice showed no change in protein levels of CnA, PP1-C, or PP2A-C (data not shown).


Gene Relative mRNA levels (normalized to Gapdh)
WTDCM DCM/HET

CHOP (Ddit3) 100 ± 10 103 ± 3 113 ± 10
Caspase 12 (Casp12) 100 ± 7 122 ± 3*120 ± 16
HCLS1 associated protein X-1 (Hax1) 100 ± 5 91 ± 3 106 ± 12
Fatty acid binding protein 3 (Fabp3) 100 ± 7 70 ± 4*75 ± 7*
Carnitine palmitoyltransferase 1 (Cpt1b) 100 ± 2 77 ± 3*70 ± 8*
Glucose transporter 4 (Slc2a4) 100 ± 12 88 ± 2 95 ± 8

Heart RNA from wild-type (WT) mice, transgenic mice expressing Glu154Lys mutant α-tropomyosin (DCM), and DCM/Atp2a2+/− double mutant (DCM/HET) mice was analyzed by RT-PCR. Values are mean ± SE; = at least 4 for each genotype; * < 0.05 versus WT controls.

4. Discussion

While there is strong evidence that ATP2A2 heterozygosity does not impair cardiovascular performance in humans either at rest or during exercise [6, 7], the opportunities to elucidate the molecular mechanisms that allow for cardiac function to be preserved in otherwise healthy DD patients are obviously limited. For example, it remains unknown if loss of one ATP2A2 allele elicits the compensatory upregulation of the second functional allele or whether SERCA2a haploinsufficiency in human heart leads to a greater, and apparently effective, reliance on transsarcolemmal Ca2+-flux. There have also been no studies to determine if DD patients are more susceptible to heart failure and decompensation in the context of secondary pathological insults. The Atp2a2 heterozygous mouse model on the inbred FVB/N background offered a unique opportunity to address these questions, as it resembles human DD patients in displaying a skin/keratinized epithelial phenotype with no overt effects on cardiovascular function.

Expression of SERCA2a protein levels at ~80% of WT levels in HET hearts demonstrated a remarkable ability to upregulate expression of the single functional Atp2a2 allele. This was unexpected given the evidence from transgenic lines that it is difficult to appreciably overexpress SERCA2 protein in mouse hearts [43, 44]. Given that Atp2a2 mRNA levels were reduced by ~50% in HET hearts, it is reasonable to assume that the increase in SERCA2a protein results principally from posttranscriptional adaptations; these could include augmented translation, extended SERCA2 protein half-life, and/or diminished SERCA2 protein degradation. The increase seen in LTCCα2 protein levels is consistent with the idea that even modest reductions in SERCA2a expression might lead to a greater reliance on Ca2+-handling across the sarcolemma. While such a shift would help preserve Ca2+-homeostasis, it is likely to place a greater energetic burden on the heart. SERCA2 is unique in its stoichiometry of transporting 2 Ca2+ ions/ATP hydrolyzed. In comparison, transsarcolemmal flux of Ca2+ via LTCC-influx, NCX1-efflux (with a stoichiometry of 3Na+ : 1Ca2+), and Na+/K+-ATPase-mediated Na+ removal effectively doubles the energy cost of Ca2+-clearance.

Increased PLN phosphorylation can also serve to compensate for the reduction in SERCA2 levels [23], with evidence of a predominant role for phosphorylation at Ser16, but not Thr17, in -adrenergic stimulation of inotropy and lusitropy in mouse hearts [45]. Therefore, it is difficult to ascribe any part of the normal -adrenergic response seen in HET hearts to increased PLN phosphorylation, given that PS16 levels were unaltered and only PT17 levels were elevated in stimulated HET hearts. While phosphorylation at Thr17 is mediated by Ca2+/calmodulin-dependent kinase CaMKII, dephosphorylation is mediated by PP1 [46, 47]. Although immunoblot analysis showed no evidence of a reduction in PP1 expression in HET hearts (data not shown), a clear reduction in PP1 expression was observed in HCM/HET hearts relative to HCM controls, probably providing some compensation for the reduction in SERCA2 protein.

Reduction in SERCA2 expression/activity is closely associated with progression of heart disease and failure. While recent clinical trials provide strong evidence that enhancing SERCA2a expression can alleviate impairment of cardiac function [4850], it remains unclear whether SERCA2a deficiency can itself precipitate decompensation and heart failure. This is highly relevant to DD patients, particularly in the context of aging or secondary pathological conditions affecting the heart. Hypothyroidism, which affects about 4.6% of the US population [51], is one such condition known to compromise cardiac function [13, 24] and reduce SERCA2 expression [20, 25]. The finding that Atp2a2 heterozygosity does not exacerbate the effects of hypothyroidism in mice may result from the switch in myosin heavy chain (MHC) isoforms from -MHC to the slower -MHC, which occurs in hypothyroidism, and is known to be energetically favorable [52]. Whether the effects of hypothyroidism are similarly unaffected by SERCA2 haploinsufficiency in human DD patients is an issue that remains to be clarified; it should be evaluated with no preconceptions, as the lack of an effect in the rodent model does not discount possible consequences in human DD patients.

A relative increase in -MHC levels, which commonly occurs in diseased conditions, renders hearts more susceptible to chronic myocardial stress [53]. Although this outcome was not tested in the context of hypothyroidism in HET mice, we investigated the effects of Atp2a2 heterozygosity in models of altered myofibrillar Ca2+-sensitivity, which impose significant chronic contractile stress and are closely associated with the pathogenesis of cardiomyopathies and heart failure [54]. DCM mice, with reduced myofibrillar Ca2+-sensitivity, have been reported to develop hypertrophy at 2 months of age, with significant dilation and myocyte disarray occurring by 5 months and mice starting to die at 4–6 months of age [16]. These effects were shown to be associated with downregulation of SERCA2a, consistent with the possibility that Atp2a2 heterozygosity would hasten disease pathogenesis. The absence of such an effect in DCM/HET mice however revealed that SERCA2 haploinsufficiency has limited effects in the context of reduced myofibrillar Ca2+-sensitivity, which occurs during pathological conditions such as inflammation and sepsis [55].

The rapid onset of hypertrophy and decompensation in HCM/HET mice on the other hand strongly suggests that disease pathogenesis associated with increased myofibrillar Ca2+-sensitivity may be exacerbated in DD patients. The catastrophic effects of SERCA2 haploinsufficiency in HCM/HET occurred despite SERCA2a protein levels being reduced by just 23% compared to levels in HCM hearts. This indicates that relatively modest reductions in SERCA2a expression can have profound effects in hearts with increased myofibrillar Ca2+-sensitivity. This effect is likely due to the fact that, besides factors such as mechanical load and sarcolemmal Ca2+-flux, dissociation of Ca2+ from myofibrils is facilitated by SERCA2-mediated Ca2+-clearance [56]. The importance of this function is expected to be amplified in the context of elevated myofibrillar Ca2+-sensitivity, making even small changes in SERCA2 expression/function highly consequential. Recent reports that elevating SERCA2 activity, either by increased expression of SERCA2a or ablation of phospholamban, attenuates disease progression in HCM mice [57, 58] are consistent with this hypothesis.

Perturbations in cytosolic Ca2+-clearance are also associated with the generation of ventricular arrhythmias [56], which are strongly implicated in progression to heart failure and sudden death [59, 60]. Targeted SERCA2a gene therapy has been shown, in multiple models, to reduce ventricular arrhythmias in addition to improving cardiac function [4]. The highly advanced disease condition observed in HCM/HET mice as young as 4 weeks of age precluded effective functional analyses of these mice. However, we examined left ventricular pressure measurements in HET mice and found no evidence of extrasystolic beats or other arrhythmias under either basal conditions or upon maximal -adrenergic stimulation (data not shown).

The more rapid decompensation in HCM/HET hearts was associated with a reversal of the increase in Orai1 and Stim1 levels seen in HCM hearts. The incidence of increased SOCE via ORAI1 and STIM1 in pathological hypertrophy has implicated these proteins in disease pathogenesis [31]. However, recent data from knockout models reveal a more nuanced role for these proteins in heart, with effects on Ca2+-homeostasis and the development of compensatory hypertrophy [61, 62]. Orai1 deficiency was found to exacerbate loss of cardiac function and hasten progression to dilation and was associated with increased apoptosis [63]. Indeed, levels of proapoptotic Chop and Casp12 were elevated in HCM/HET hearts and notably expression of antiapoptotic Hax1, which was elevated in HCM hearts, was reduced to WT levels in HCM/HET hearts. There is increasing evidence that the antiapoptotic function of the HAX1 protein is linked to its association with SR Ca2+-handling [37, 64], where HAX1 has been shown to localize to the SR in a PLN-dependent manner [65]. HAX1 overexpression, which promotes cell survival, downregulates SERCA2 protein levels, whereas SERCA2 overexpression has been shown to antagonize its protective effects [66, 67]. Therefore, the reversion of HAX1 expression to WT levels may contribute to the preservation of SERCA2 levels in HCM/HET hearts, with potentially maladaptive effects on myocyte cell survival. Further detailed studies will be necessary to fully elucidate possible interactions between HAX1, which has been localized to mitochondria as well [37], and SERCA2 during HCM pathogenesis. Additional perturbations in myocardial energy metabolism, which are strongly implicated in hypertrophy and heart failure [3841], are also likely to contribute to the rapid decompensation observed in HCM/HET hearts. Reductions in both CPT1b and GLUT4 have been shown to promote pathological hypertrophy and heart failure [6870]. Conversely, we have recently demonstrated that protection against Tm180-related hypertrophy is associated with preservation of CPT1b and GLUT4 expression at WT levels [23].

In conclusion, our data show that the loss of one copy of the Atp2a2 gene, which causes reduced expression of SERCA2a in heart, appears to be benign under normal conditions and even in some disease states. This finding is consistent with the results of studies in human DD patients, in which the loss of one ATP2a2 allele caused no impairment of cardiac performance [6, 7]. However, our studies with the mouse model of DD also reveal that loss of a single copy of Atp2a2 can lead to much more rapid decompensation, heart failure, and death in mice carrying an HCM mutation that increases myofibrillar Ca2+ sensitivity. These results suggest that DD patients may be less tolerant of the changes associated with increased myofibrillar Ca2+-sensitivity in heart. In addition to being relevant to pathological conditions such as end-stage heart failure [15], the implications of this finding could extend to the use of therapeutic agents that enhance myofibrillar Ca2+-sensitivity in DD patients. For example, although long-term treatment with the Ca2+-sensitizer levosimendan improves cardiac function in a model with cardiomyocyte-specific ablation of SERCA2, it also significantly increases fibrosis in SERCA2-deficient hearts [71]. While extrapolation of results from rodent models to human disease merits caution, our results suggest that progression of some types of heart disease is likely to be exacerbated by DD mutations. DD patients and their physicians should therefore be aware of the possibility of adverse interactions between SERCA2 haploinsufficiency and certain pathological conditions affecting cardiovascular health.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by National Institutes of Health Grants HL061974 (GES) and HL107957 (YW), an American Heart Association Beginning Grant-in-Aid 11BGIA77220005 (VP), and a Near Horizons Pilot grant from the University of Cincinnati Heart, Lung and Vascular Institute (VP and JNL). The authors thank Maureen Bender for excellent animal husbandry.

References

  1. A. Sakuntabhai, V. Ruiz-Perez, S. Carter et al., “Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease,” Nature Genetics, vol. 21, no. 3, pp. 271–277, 1999. View at: Publisher Site | Google Scholar
  2. A. Hovnanian, “Darier's disease: from dyskeratosis to endoplasmic reticulum calcium ATPase deficiency,” Biochemical and Biophysical Research Communications, vol. 322, no. 4, pp. 1237–1344, 2004. View at: Publisher Site | Google Scholar
  3. M. Periasamy, P. Bhupathy, and G. J. Babu, “Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology,” Cardiovascular Research, vol. 77, no. 2, pp. 265–273, 2008. View at: Publisher Site | Google Scholar
  4. M. B. Sikkel, C. Hayward, K. T. MacLeod, S. E. Harding, and A. R. Lyon, “SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope,” British Journal of Pharmacology, vol. 171, no. 1, pp. 38–54, 2014. View at: Publisher Site | Google Scholar
  5. Y. Miyauchi, T. Daiho, K. Yamasaki et al., “Comprehensive analysis of expression and function of 51 sarco(endo)plasmic reticulum Ca2+-ATPase mutants associated with darier disease,” The Journal of Biological Chemistry, vol. 281, no. 32, pp. 22882–22895, 2006. View at: Publisher Site | Google Scholar
  6. S. Tavadia, R. C. Tait, T. A. McDonagh, and C. S. Munro, “Platelet and cardiac function in Darier's disease,” Clinical and Experimental Dermatology, vol. 26, no. 8, pp. 696–699, 2001. View at: Publisher Site | Google Scholar
  7. B. M. Mayosi, A. Kardos, C. H. Davies et al., “Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure,” Heart, vol. 92, no. 1, pp. 105–109, 2006. View at: Publisher Site | Google Scholar
  8. M. Periasamy, T. D. Reed, L. H. Liu et al., “Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene,” Journal of Biological Chemistry, vol. 274, no. 4, pp. 2556–2562, 1999. View at: Publisher Site | Google Scholar
  9. L. H. Liu, G. P. Boivin, V. Prasad, M. Periasamy, and G. E. Shull, “Squamous cell tumors in mice heterozygous for a null allele of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump,” Journal of Biological Chemistry, vol. 276, no. 29, pp. 26737–26740, 2001. View at: Publisher Site | Google Scholar
  10. V. Prasad, G. P. Boivin, M. L. Miller et al., “Haploinsufficiency of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump, predisposes mice to squamous cell tumors via a novel mode of cancer susceptibility,” Cancer Research, vol. 65, no. 19, pp. 8655–8661, 2005. View at: Publisher Site | Google Scholar
  11. J. E. J. Schultz, B. J. Glascock, S. A. Witt et al., “Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 286, no. 3, pp. H1146–H1153, 2004. View at: Google Scholar
  12. S. Huke, L. H. Liu, D. Biniakiewicz, W. T. Abraham, and M. Periasamy, “Altered force-frequency response in non-failing hearts with decreased SERCA pump-level,” Cardiovascular Research, vol. 59, no. 3, pp. 668–677, 2003. View at: Publisher Site | Google Scholar
  13. J. N. Lorenz and J. Robbins, “Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 272, no. 3, pp. H1137–H1146, 1997. View at: Google Scholar
  14. D. Fatkin and R. M. Graham, “Molecular mechanisms of inherited cardiomyopathies,” Physiological Reviews, vol. 82, no. 4, pp. 945–980, 2002. View at: Google Scholar
  15. J. van der Velden, Z. Papp, R. Zaremba et al., “Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins,” Cardiovascular Research, vol. 57, no. 1, pp. 37–47, 2003. View at: Publisher Site | Google Scholar
  16. S. Rajan, R. P. H. Ahmed, G. Jagatheesan et al., “Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity,” Circulation Research, vol. 101, no. 2, pp. 205–214, 2007. View at: Publisher Site | Google Scholar
  17. T. M. Olson, N. Y. Kishimoto, F. G. Whitby, and V. V. Michels, “Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 4, pp. 723–732, 2001. View at: Publisher Site | Google Scholar
  18. R. Prabhakar, G. P. Boivin, I. L. Grupp et al., “A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 10, pp. 1815–1828, 2001. View at: Publisher Site | Google Scholar
  19. L. Thierfelder, H. Watkins, C. MacRae et al., “Alpha-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere,” Cell, vol. 77, no. 5, pp. 701–712, 1994. View at: Publisher Site | Google Scholar
  20. T. D. Reed, G. J. Babu, Y. Ji et al., “The expression of SR calcium transport ATpase and the Na+/Ca2+ exchanger are antithetically regulated during mouse cardiac development and in hypo/hyperthyroidism,” Journal of Molecular and Cellular Cardiology, vol. 32, no. 3, pp. 453–464, 2000. View at: Publisher Site | Google Scholar
  21. A. N. Wansapura, V. M. Lasko, J. B. Lingrel, and J. N. Lorenz, “Mice expressing ouabain-sensitive α1-Na,K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 300, no. 1, pp. H347–H355, 2011. View at: Publisher Site | Google Scholar
  22. N. J. Al Moamen, V. Prasad, I. Bodi et al., “Loss of the AE3 anion exchanger in a hypertrophic cardiomyopathy model causes rapid decompensation and heart failure,” Journal of Molecular and Cellular Cardiology, vol. 50, no. 1, pp. 137–146, 2011. View at: Publisher Site | Google Scholar
  23. V. Prasad, J. N. Lorenz, V. M. Lasko et al., “Ablation of plasma membrane Ca2+-ATPase isoform 4 prevents development of hypertrophy in a model of hypertrophic cardiomyopathy,” Journal of Molecular and Cellular Cardiology, vol. 77, pp. 53–63, 2014. View at: Publisher Site | Google Scholar
  24. D. H. MacLennan and E. G. Kranias, “Phospholamban: a crucial regulator of cardiac contractility,” Nature Reviews Molecular Cell Biology, vol. 4, no. 7, pp. 566–577, 2003. View at: Publisher Site | Google Scholar
  25. I. Klein and S. Danzi, “Thyroid disease and the heart,” Circulation, vol. 116, no. 15, pp. 1725–1735, 2007. View at: Publisher Site | Google Scholar
  26. M. Arai, K. Otsu, D. H. MacLennan, N. R. Alpert, and M. Periasamy, “Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins,” Circulation Research, vol. 69, no. 2, pp. 266–276, 1991. View at: Publisher Site | Google Scholar
  27. H. Kögler and J. C. Rüegg, “Cardiac contractility: modulation of myofibrillar calcium sensitivity by β-adrenergic stimulation,” Israel Journal of Medical Sciences, vol. 33, no. 1, pp. 1–7, 1997. View at: Google Scholar
  28. K. Brixius, P. Savvidou-Zaroti, U. Mehlhorn, W. Bloch, E. G. Kranias, and R. H. G. Schwinger, “Increased Ca2+-sensitivity of myofibrillar tension in heart failure and its functional implication,” Basic Research in Cardiology, vol. 97, supplement 1, pp. I111–I117, 2002. View at: Google Scholar
  29. M. Endoh, “Cardiac Ca2+ signaling and Ca2+ sensitizers,” Circulation Journal, vol. 72, no. 12, pp. 1915–1925, 2008. View at: Publisher Site | Google Scholar
  30. S. A. Goonasekera and J. D. Molkentin, “Unraveling the secrets of a double life: contractile versus signaling Ca2+ in a cardiac myocyte,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 2, pp. 317–322, 2012. View at: Publisher Site | Google Scholar
  31. F. R. Giachini, V. V. Lima, J. L. Hannan, F. S. Carneiro, R. C. Webb, and R. C. Tostes, “STIM1/Orai1-mediated store-operated Ca2+ entry: the tip of the iceberg,” Brazilian Journal of Medical and Biological Research, vol. 44, no. 11, pp. 1080–1087, 2011. View at: Publisher Site | Google Scholar
  32. J. Soboloff, B. S. Rothberg, M. Madesh, and D. L. Gill, “STIM proteins: dynamic calcium signal transducers,” Nature Reviews Molecular Cell Biology, vol. 13, no. 9, pp. 549–565, 2012. View at: Publisher Site | Google Scholar
  33. J. D. Molkentin, J. R. Lu, C. L. Antos et al., “A calcineurin-dependent transcriptional pathway for cardiac hypertrophy,” Cell, vol. 93, no. 2, pp. 215–228, 1998. View at: Publisher Site | Google Scholar
  34. J. Neumann, T. Eschenhagen, L. R. Jones et al., “Increased expression of cardiac phosphatases in patients with end-stage heart failure,” Journal of Molecular and Cellular Cardiology, vol. 29, no. 1, pp. 265–272, 1997. View at: Publisher Site | Google Scholar
  35. M. Yamada, Y. Ikeda, M. Yano et al., “Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy.,” The FASEB Journal, vol. 20, no. 8, pp. 1197–1199, 2006. View at: Publisher Site | Google Scholar
  36. U. Gergs, P. Boknik, I. Buchwalow et al., “Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function,” Journal of Biological Chemistry, vol. 279, no. 39, pp. 40827–40834, 2004. View at: Publisher Site | Google Scholar
  37. S. V. Yap, E. Vafiadaki, J. Strong, and A. Kontrogianni-Konstantopoulos, “HAX-1: a multifaceted antiapoptotic protein localizing in the mitochondria and the sarcoplasmic reticulum of striated muscle cells,” Journal of Molecular and Cellular Cardiology, vol. 48, no. 6, pp. 1266–1279, 2010. View at: Publisher Site | Google Scholar
  38. A. Kataoka, C. Hemmer, and P. B. Chase, “Computational simulation of hypertrophic cardiomyopathy mutations in Troponin I: influence of increased myofilament calcium sensitivity on isometric force, ATPase and [Ca2+]i,” Journal of Biomechanics, vol. 40, no. 9, pp. 2044–2052, 2007. View at: Publisher Site | i&author=A. Kataoka&author=C. Hemmer&author=&author=P. B. Chase&publication_year=2007" target="_blank">Google Scholar
  39. J. G. Crilley, E. A. Boehm, E. Blair et al., “Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy,” Journal of the American College of Cardiology, vol. 41, no. 10, pp. 1776–1782, 2003. View at: Publisher Site | Google Scholar
  40. C. Ferrantini, A. Belus, N. Piroddi, B. Scellini, C. Tesi, and C. Poggesi, “Mechanical and energetic consequences of HCM-causing mutations,” Journal of Cardiovascular Translational Research, vol. 2, no. 4, pp. 441–451, 2009. View at: Publisher Site | Google Scholar
  41. B. N. Finck, “The PPAR regulatory system in cardiac physiology and disease,” Cardiovascular Research, vol. 73, no. 2, pp. 269–277, 2007. View at: Publisher Site | Google Scholar
  42. G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley, “Myocardial fatty acid metabolism in health and disease,” Physiological Reviews, vol. 90, no. 1, pp. 207–258, 2010. View at: Publisher Site | Google Scholar
  43. H. He, F. J. Giordano, R. Hilal-Dandan et al., “Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation,” The Journal of Clinical Investigation, vol. 100, no. 2, pp. 380–389, 1997. View at: Publisher Site | Google Scholar
  44. D. L. Baker, K. Hashimoto, I. L. Grupp et al., “Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts,” Circulation Research, vol. 83, no. 12, pp. 1205–1214, 1998. View at: Publisher Site | Google Scholar
  45. G. Chu, J. W. Lester, K. B. Young, W. Luo, J. Zhai, and E. G. Kranias, “A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to β-agonists,” Journal of Biological Chemistry, vol. 275, no. 49, pp. 38938–38943, 2000. View at: Publisher Site | Google Scholar
  46. C. Mundiña-Weilenmann, L. Vittone, M. Ortale, G. C. de Cingolani, and A. Mattiazzi, “Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart,” The Journal of Biological Chemistry, vol. 271, no. 52, pp. 33561–33567, 1996. View at: Publisher Site | Google Scholar
  47. A. Mattiazzi, C. Mundiña-Weilenmann, C. Guoxiang, L. Vittone, and E. Kranias, “Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions,” Cardiovascular Research, vol. 68, no. 3, pp. 366–375, 2005. View at: Publisher Site | Google Scholar
  48. A. Papolos and W. H. Frishman, “Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure,” Cardiology in Review, vol. 21, no. 3, pp. 151–154, 2013. View at: Publisher Site | Google Scholar
  49. K. Zsebo, A. Yaroshinsky, J. J. Rudy et al., “Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality,” Circulation Research, vol. 114, no. 1, pp. 101–108, 2014. View at: Publisher Site | Google Scholar
  50. B. Greenberg, A. Yaroshinsky, K. M. Zsebo et al., “Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b),” Journal of the American College of Cardiology: Heart Failure, vol. 2, no. 1, pp. 84–92, 2014. View at: Publisher Site | Google Scholar
  51. S. H. Golden, K. A. Robinson, I. Saldanha, B. Anton, and P. W. Ladenson, “Prevalence and incidence of endocrine and metabolic disorders in the united states: a comprehensive review,” Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 6, pp. 1853–1878, 2009. View at: Publisher Site | Google Scholar
  52. C. Holubarsch, R. P. Goulette, R. Z. Litten, B. J. Martin, L. A. Mulieri, and N. R. Alpert, “The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium,” Circulation Research, vol. 56, no. 1, pp. 78–86, 1985. View at: Publisher Site | Google Scholar
  53. M. Krenz and J. Robbins, “Impact of beta-myosin heavy chain expression on cardiac function during stress,” Journal of the American College of Cardiology, vol. 44, no. 12, pp. 2390–2397, 2004. View at: Publisher Site | Google Scholar
  54. K. A. Palmiter and R. J. Solaro, “Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutations causal for familial hypertrophic cardiomyopathy,” Basic Research in Cardiology, Supplement, vol. 92, supplement 1, pp. 63–74, 1997. View at: Publisher Site | Google Scholar
  55. L.-L. Wu, C. Tang, and M.-S. Liu, “Altered phosphorylation and calcium sensitivity of cardiac myofibrillar proteins during sepsis,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 281, no. 2, pp. R408–R416, 2001. View at: Google Scholar
  56. H. E. D. J. Ter Keurs and P. A. Boyden, “Calcium and arrhythmogenesis,” Physiological Reviews, vol. 87, no. 2, pp. 457–506, 2007. View at: Publisher Site | Google Scholar
  57. J. R. Peña, A. C. Szkudlarek, C. M. Warren et al., “Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy,” Journal of Molecular and Cellular Cardiology, vol. 49, no. 6, pp. 993–1002, 2010. View at: Publisher Site | Google Scholar
  58. R. D. Gaffin, J. R. Peña, M. S. L. Alves et al., “Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 5, pp. 812–820, 2011. View at: Publisher Site | Google Scholar
  59. J. M. McLenachan, E. Henderson, K. I. Morris, and H. J. Dargie, “Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy,” The New England Journal of Medicine, vol. 317, no. 13, pp. 787–792, 1987. View at: Publisher Site | Google Scholar
  60. A. Curcio, D. Torella, C. Iaconetti et al., “MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts,” PLoS ONE, vol. 8, no. 7, Article ID e70158, 2013. View at: Publisher Site | Google Scholar
  61. H. E. Collins, X. Zhu-Mauldin, R. B. Marchase, and J. C. Chatham, “STIM1/Orai1-mediated SOCE: current perspectives and potential roles in cardiac function and pathology,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 305, no. 4, pp. H446–H458, 2013. View at: Publisher Site | Google Scholar
  62. H. E. Collins, L. He, L. Zou et al., “Stromal interaction molecule 1 is essential for normal cardiac homeostasis through modulation of ER and mitochondrial function,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 306, no. 8, pp. H1231–H1239, 2014. View at: Publisher Site | Google Scholar
  63. J. S. Horton, C. L. Buckley, E. M. Alvarez, A. Schorlemmer, and A. J. Stokes, “The calcium release-activated calcium channel Orai1 represents a crucial component in hypertrophic compensation and the development of dilated cardiomyopathy,” Channels, vol. 8, no. 1, pp. 35–48, 2014. View at: Publisher Site | Google Scholar
  64. E. Vafiadaki, D. A. Arvanitis, S. N. Pagakis et al., “The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates Its protein levels to promote cell survival,” Molecular Biology of the Cell, vol. 20, no. 1, pp. 306–318, 2009. View at: Publisher Site | Google Scholar
  65. E. Vafiadaki, D. Sanoudou, D. A. Arvanitis, D. H. Catino, E. G. Kranias, and A. Kontrogianni-Konstantopoulos, “Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function,” Journal of Molecular Biology, vol. 367, no. 1, pp. 65–79, 2007. View at: Publisher Site | Google Scholar
  66. E. Vafiadaki, D. A. Arvanitis, S. N. Pagakis et al., “The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival,” Molecular Biology of the Cell, vol. 20, no. 1, pp. 306–318, 2009. View at: Publisher Site | Google Scholar
  67. W. Zhao, J. R. Waggoner, Z.-G. Zhang et al., “The anti-apoptotic protein HAX-1 is a regulator of cardiac function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 49, pp. 20776–20781, 2009. View at: Publisher Site | Google Scholar
  68. L. He, T. Kim, Q. Long et al., “Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity,” Circulation, vol. 126, no. 14, pp. 1705–1716, 2012. View at: Publisher Site | Google Scholar
  69. K. R. Haynie, B. Vandanmagsar, S. E. Wicks, J. Zhang, and R. L. Mynatt, “Inhibition of carnitine palymitoyltransferase1b induces cardiac hypertrophy and mortality in mice,” Diabetes, Obesity & Metabolism, vol. 16, no. 8, pp. 757–760, 2014. View at: Publisher Site | Google Scholar
  70. A. A. Domenighetti, V. R. Danes, C. L. Curl, J. M. Favaloro, J. Proietto, and L. M. D. Delbridge, “Targeted GLUT-4 deficiency in the heart induces cardiomyocyte hypertrophy and impaired contractility linked with Ca2+ and proton flux dysregulation,” Journal of Molecular and Cellular Cardiology, vol. 48, no. 4, pp. 663–672, 2010. View at: Publisher Site | Google Scholar
  71. V. Hillestad, F. Kramer, S. Golz, A. Knorr, K. B. Andersson, and G. Christensen, “Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene,” Journal of Applied Physiology, vol. 115, no. 10, pp. 1572–1580, 2013. View at: Publisher Site | Google Scholar

Copyright © 2015 Vikram Prasad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1276 Views | 618 Downloads | 10 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder